It is expected that by 2035 the number of diabetics worldwide will increase to 592 million.
US – In the world, 387 million people live with diabetes mellitus; however, the figure is expected to increase to 592 million by 2035, of which half will not know they have the disease.
Executive director of research and development of pharmaceutical Novo Nordisk, Mads Krogsgaard Thomsen, said that governments will have to fight two things in the coming years: climate change and diabetes, and should take strong measure to counter their advances.
At the annual meeting of the American Diabetes Association (ADA), held in New Orleans, he said that most of those affected by the disease are prescribed with insulin five to eight years after diagnosis.
That said, appropriate treatment can prevent many diseases, including cardiovascular, thanks to the development of drugs that have changed the prospects for quality of life.
In an interview, the Danish doctor said that Asian people, because of their genetics, are most at risk of being diabetic; they are followed Latinas.
Today the issue of diabetes remains a problem of conscience and cultural; where the multifactorial disease is gaining ground in those who do not maintain a healthy life, consistent balanced diet and constant physical activity, added the expert.
Hemoglobin is a protein having the function of transporting oxygen from the lungs to the tissues; mainly it found in red blood cells (blood cells) and is characterized by being formed by iron.
The glucose binds to hemoglobin to form glycated hemoglobin or hemoglobin A1c, which, according to the expert, at high levels there is an increased risk of cardiovascular complications, which is increased 25 percent for each additional seven points.
Krogsgaard Thomsen said that advances in medications and treatments are given by leaps and bounds; however, the idea of using insulin and lifestyle change yet permeating all those affected by the disease.
The Danish company spends about 2.2 billion dollars in research and development of drugs for diabetes, drugs that take 12 years to reach the market from the day of trial.